Makio Gamoh

774 total citations
49 papers, 484 citations indexed

About

Makio Gamoh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Makio Gamoh has authored 49 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in Makio Gamoh's work include Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (18 papers) and Gastric Cancer Management and Outcomes (18 papers). Makio Gamoh is often cited by papers focused on Colorectal Cancer Treatments and Studies (26 papers), Cancer Treatment and Pharmacology (18 papers) and Gastric Cancer Management and Outcomes (18 papers). Makio Gamoh collaborates with scholars based in Japan, United States and South Korea. Makio Gamoh's co-authors include Chikashi Ishioka, Yoshito Komatsu, Masahiro Tsuda, Hideki Shimodaira, Toshio Shimokawa, Yukinori Kurokawa, Shin Takahashi, Naotoshi Sugimoto, Hiroshi Furukawa and Hiroshi Imamura and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Makio Gamoh

48 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Makio Gamoh Japan	11	328	248	109	95	73	49	484
S. Giaquinta Italy	10	483 1.5×	463 1.9×	215 2.0×	115 1.2×	54 0.7×	24	670
Véronique Guerin‐Meyer France	10	662 2.0×	309 1.2×	177 1.6×	60 0.6×	50 0.7×	32	820
Soichi Fumita Japan	10	277 0.8×	230 0.9×	132 1.2×	130 1.4×	25 0.3×	22	468
Daisuke Korenaga Japan	12	137 0.4×	245 1.0×	194 1.8×	98 1.0×	60 0.8×	30	445
E Piana Italy	11	390 1.2×	340 1.4×	109 1.0×	65 0.7×	47 0.6×	28	592
Katia Dotti Italy	12	364 1.1×	149 0.6×	99 0.9×	18 0.2×	114 1.6×	28	514
B-Y. Ryoo South Korea	9	313 1.0×	332 1.3×	166 1.5×	115 1.2×	83 1.1×	36	581
David E. Adelberg United States	13	317 1.0×	305 1.2×	170 1.6×	106 1.1×	59 0.8×	37	542
M.-H. Ryu South Korea	13	295 0.9×	364 1.5×	196 1.8×	140 1.5×	55 0.8×	27	578
Carlo Barone Italy	13	210 0.6×	200 0.8×	66 0.6×	63 0.7×	32 0.4×	20	394

Countries citing papers authored by Makio Gamoh

Since Specialization

Citations

This map shows the geographic impact of Makio Gamoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Makio Gamoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Makio Gamoh more than expected).

Fields of papers citing papers by Makio Gamoh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Makio Gamoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Makio Gamoh. The network helps show where Makio Gamoh may publish in the future.

Co-authorship network of co-authors of Makio Gamoh

This figure shows the co-authorship network connecting the top 25 collaborators of Makio Gamoh. A scholar is included among the top collaborators of Makio Gamoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Makio Gamoh. Makio Gamoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kato, Takeshi, Yoshinori Kagawa, Yasutoshi Kuboki, et al.. (2021). Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study. International Journal of Clinical Oncology. 26(7). 1238–1247. 3 indexed citations

Harada, Toshiyuki, Hisao Imai, Soichi Fumita, et al.. (2020). Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer. International Journal of Clinical Oncology. 26(1). 104–110. 9 indexed citations

Fumita, Soichi, Hisao Imai, Toshiyuki Harada, et al.. (2019). Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer. Journal of Pain and Symptom Management. 59(5). 1043–1051.e2. 10 indexed citations

Endo, Shunji, Yukinori Kurokawa, Makio Gamoh, et al.. (2019). Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. Anticancer Research. 39(2). 1059–1065. 9 indexed citations

Yoshino, Takayuki, Takeharu Yamanaka, Manabu Shiozawa, et al.. (2019). ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC). Annals of Oncology. 30. v199–v199. 2 indexed citations

Kotaka, Masahito, Takeharu Yamanaka, Takayuki Yoshino, et al.. (2018). Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open. 3(3). e000354–e000354. 19 indexed citations

Yoshino, Takayuki, Takeharu Yamanaka, Masahito Kotaka, et al.. (2017). Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. Annals of Oncology. 28. v614–v614. 6 indexed citations

Komatsu, Yoshito, Atsuo Takashima, Tadamichi Denda, et al.. (2017). Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Annals of Oncology. 28. v158–v158. 4 indexed citations

Komatsu, Yoshito, Chikashi Ishioka, Ken Shimada, et al.. (2015). Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer. 15(1). 626–626. 10 indexed citations

10.

Shimodaira, Hideki, Makio Gamoh, Hideaki Ando, et al.. (2014). Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on <b><i>KRAS</i></b> Mutation Status (T-CORE0801). Oncology. 87(1). 7–20. 16 indexed citations

11.

Kurokawa, Yukinori, Naotoshi Sugimoto, Hiroto Miwa, et al.. (2014). Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). British Journal of Cancer. 110(5). 1163–1168. 106 indexed citations

12.

Takahashi, Mamoru, Yoshikazu Takahashi, Hisatsugu Ohori, & Makio Gamoh. (2013). Serum HER2ECD Levels in Patients with Advanced Gastric Cancer Treated with Trastuzumab as First-Line Therapy. Annals of Oncology. 24. ix92–ix92. 1 indexed citations

13.

Takahashi, Yoshikazu, Hisatsugu Ohori, Mamoru Takahashi, & Makio Gamoh. (2013). Serum HER2 Extracellular Domain Levels and Tissue HER2 Overexpression in Advanced Gastric Cancer Patients. Annals of Oncology. 24. ix31–ix31. 1 indexed citations

14.

Kato, Shunsuke, Makio Gamoh, Takuhiro Yamaguchi, et al.. (2012). Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients. Oncology. 83(2). 101–107. 9 indexed citations

15.

Shimodaira, Hideki, Mika Watanabe, Takao Suzuki, et al.. (2012). Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology. 18(4). 670–677. 31 indexed citations

16.

Kato, Shunsuke, Makio Gamoh, Takuhiro Yamaguchi, et al.. (2011). A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702.. Journal of Clinical Oncology. 29(4_suppl). 496–496. 2 indexed citations

17.

Gamoh, Makio, T. Yamaguchi, Yusuke Sasaki, et al.. (2011). A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 plus bevacizumab (IRIS+BV) and modified FOLFIRI plus BV (mFOLFIRI+BV) in patients (pts) with metastatic colorectal cancer (mCRC): The result of efficacy report of T-CORE0702.. Journal of Clinical Oncology. 29(15_suppl). e14001–e14001. 3 indexed citations

18.

Yoshioka, Takashi, Shunsuke Kato, Makio Gamoh, et al.. (2009). Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. British Journal of Cancer. 101(12). 1972–1977. 17 indexed citations

19.

Yoshioka, Takashi, Yuh Sakata, Masanori Terashima, et al.. (2003). Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gastric Cancer. 6(3). 153–158. 9 indexed citations

20.

Chen, Dong‐Yi, et al.. (1990). Evaluation of Mizoribine as an Immunosuppressant in Subrenal Capsule Assay Using Immunocompetent Mice. Japanese Journal of Cancer Research. 81(2). 183–187. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact